BeiGene Net Cash Flow 2014-2024 | ONC
BeiGene annual/quarterly net cash flow history and growth rate from 2014 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
- BeiGene net cash flow for the quarter ending September 30, 2024 was $-0.473B, a 40.49% decline year-over-year.
- BeiGene net cash flow for the twelve months ending September 30, 2024 was $-2.108B, a 1.03% increase year-over-year.
- BeiGene annual net cash flow for 2023 was $-0.689B, a 35.68% increase from 2022.
- BeiGene annual net cash flow for 2022 was $-0.508B, a 116.97% decline from 2021.
- BeiGene annual net cash flow for 2021 was $2.993B, a 289.08% increase from 2020.
BeiGene Annual Net Cash Flow
(Millions of US $) |
| 2023 |
$-689 |
| 2022 |
$-508 |
| 2021 |
$2,993 |
| 2020 |
$769 |
| 2019 |
$-120 |
| 2018 |
$501 |
| 2017 |
$152 |
| 2016 |
$70 |
| 2015 |
$4 |
| 2014 |
$10 |
| 2013 |
$3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
